Dana Farber/Harvard Cancer Consortium Career Development Program in Clinical Oncology

达纳法伯/哈佛大学癌症联盟临床肿瘤学职业发展计划

• 批准号: 10376817
• 负责人: BRUCE ALLAN CHABNER
• 金额: $ 74.97万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-09-27 至 2023-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10376817
• 关键词: Adult; Advisory Committees; Appointment; Clinical; Clinical Investigator; Clinical Medicine; Clinical Oncology; Clinical Trials; Data Science; Development Plans; Discipline; Faculty; Funding; Goals; Grant; Hematology; Institutes; Institution; Laboratories; Laboratory Research; Leadership; Malignant Neoplasms; Medicine; Mentored Clinical Scientist Development Program; Mentors; Monitor; Oncology; Output; Pediatric Hematology; Performance; Population Sciences; Positioning Attribute; Productivity; Program Development; Progress Reports; Publications; Radiation Oncology; Recommendation; Records; Request for Applications; Research; Research Personnel; Research Training; Role; SECTM1 gene; Science; Training; Woman; Work; cancer clinical trial; career development; clinical investigation; design; faculty mentor; member; molecular oncology; next generation; programs; recruit; research and development

Dana Farber/Harvard Cancer Consortium Career Development Program in Clinical Oncology Project Summary/Abstract The goal of the Dana Farber/Harvard Cancer Consortium Career Development Program in Clinical Oncology (DF/HCC K12) is to prepare the next generation of clinical investigators in oncology to work at the interface of laboratory science, clinical medicine, and population science. The DF/HCC K12 was first funded in 2002 and has supported 23 Scholars, with an additional 12 Scholars who received 2 years of support through a Federal Share mechanism. The Program emphasizes research training in molecular oncology and its application to clinical medicine. The 18 K12-funded Scholars who completed participation have been exceptionally successful, with an output of 564 publications, 77 grants, and all Scholars progressing to independent faculty positions. We propose the renewal of this K12 to continue training clinicians from diverse disciplines, including adult hematology/oncology, pediatric hematology/oncology, and radiation oncology to design and conduct hypothesis-driven clinical oncology trials. To enhance our highly successful K12 program, we propose the following Specific Aims: Aim 1: We will recruit and select a diverse group of K12 Scholars. We will issue an annual Request for Applications (RFA) using a variety of mechanisms to reach the widest possible audience of candidates. We will aggressively promote the participation of women and other groups traditionally under-represented in medicine. Eligible candidates come from a large and highly qualified pool, including senior fellows and junior faculty within Dana Farber/Harvard Cancer Consortium (DF/HCC) institutions who have completed subspecialty clinical training. Non-clinician postdoctoral researchers are not eligible for participation. An Internal Advisory Committee (IAC), comprised of 20 DF/HCC faculty members with leadership roles and established track records in original research and mentoring, will assist Program Leadership with Scholar selection. We request a continuation of support for five Scholars per year with five year appointments. Aim 2: We will provide a program of rigorous didactic training, career development, and mentored clinical oncology research. Each Scholar will be guided by two Faculty Mentors, one for laboratory (or data science) training, and one for clinical investigation. A group of 34 highly qualified and motivated Faculty Mentors have been identified, but Scholars may elect to include additional mentors from the pool of >1,100 investigators within the seven DF/HCC institutions, as well as faculty from the Koch Institute at MIT and the Broad Institute of Harvard and MIT. An individualized career development plan will be devised that includes components of required and optional didactic training, hands-on laboratory research, and development of a clinical trial. Scholars will share results and participate in networking activities at an annual retreat. Aim 3: We will monitor the performance and refine the K12 Program to optimize recruitment and training of new investigators in clinical oncology research. The IAC will review annual progress reports from Scholars and Mentors and make recommendations for changes in mentoring and/or research focus, as needed. An External Advisory Committee (EAC), comprised of five PIs from other successful K12 Programs, will evaluate Program performance, participate in the annual retreat, and provide recommendations for Program enhancements to the K12 Leadership. The Program will track Scholar productivity, including presentations, publications, grants, and clinical trial activity on an annual basis.

Dana Farber/哈佛癌症联盟临床肿瘤学职业发展计划 项目摘要/摘要 达纳·法伯/哈佛癌症联盟临床肿瘤学职业发展计划的目标 (DF/HCC K12)是为下一代肿瘤学临床研究人员做准备，以便在 实验室科学、临床医学和人口科学。DF/HCCK12于2002年首次获得资金， 资助了23名奖学金获得者，另外12名奖学金获得者通过联邦 共享机制。该计划强调分子肿瘤学的研究培训及其在 临床医学。完成参与的18名K12资助的奖学金获得者 成功，出版了564份出版物，77份赠款，所有学者都晋升为独立教职员工 各就各位。我们建议更新K12，以继续培训来自不同学科的临床医生，包括 成人血液学/肿瘤学、儿童血液学/肿瘤学和放射肿瘤学设计和实施 假设驱动的临床肿瘤学试验。为了加强我们非常成功的K12计划，我们建议 以下是具体目标： 目标1：我们将招募和挑选不同的K12学者群体。我们将每年发布一份申请， 应用程序(RFA)使用各种机制接触到尽可能广泛的应聘者。我们 将积极促进妇女和其他传统上代表不足的群体的参与 医药。符合条件的候选人来自一大批高素质人才，包括高级研究员和初级研究员。 Dana Farber/哈佛癌症联盟(DF/HCC)机构中已完成 专科临床培训。非临床医生博士后研究人员没有资格参加。一个 内部咨询委员会(IAC)，由20名担任领导职务的DF/HC教职员工和 在原创研究和指导方面建立了跟踪记录，将与学者一起协助项目领导 选择。我们要求继续支持每年五名奖学金获得者，任期五年。 目标2：我们将提供严格的教学培训、职业发展和辅导计划 临床肿瘤学研究。每名学者将由两名教师指导，一名负责实验室(或数据) 科学)培训，一个用于临床研究。由34名高素质和上进心的教师组成的团队 已经确定了导师，但学者们可能会选择从1100人中选择更多的导师 七个DF/HCC机构的调查人员，以及麻省理工学院科赫研究所和 哈佛大学和麻省理工学院博德学院。将制定个性化的职业发展计划，包括 必备和可选教学培训的组成部分，动手实验室研究，以及开发 临床试验。学者们将在一年一度的静修中分享成果并参与网络活动。 目标3：我们将监控绩效并细化K12计划，以优化招聘和 培训临床肿瘤学研究方面的新研究员。咨询委员会将审查年度进度报告 来自学者和导师的建议，并就指导和/或研究重点的变化提出建议，如 需要的。外部咨询委员会(EAC)，由来自其他成功的K12计划的五名PI组成， 将评估计划绩效，参加年度务虚会，并为 K12领导层的计划增强。该计划将跟踪学者的工作效率，包括 每年的报告、出版物、赠款和临床试验活动。